Gilead First: How a Monopoly on Remdesivir Led to Rationing

What happens when one corporation is given a monopoly on a potentially useful treatment during a pandemic is the question posed in this report, which traces the case of remdesivir for COVID-19, of which there is currently a shortage and use is being rationed.

Source:

Public Citizen